{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:05:49Z","timestamp":1772157949023,"version":"3.50.1"},"posted":{"date-parts":[[2020,12,7]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":21,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2020,12,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a pandemic of the respiratory disease coronavirus disease 2019 (COVID-19). Antibody testing is essential to identify persons exposed to the virus and potentially in predicting disease immunity. 183 COVID-19 patients (68 of whom required mechanical ventilation) and 41 controls were tested for plasma IgG, IgA and IgM against the SARS-CoV-2 S1, S2, receptor binding domain (RBD) and N proteins using the MILLIPLEX\n                  <jats:sup>\u00ae<\/jats:sup>\n                  SARS-CoV-2 Antigen Panel. Plasma cytokines were concurrently measured using the MILLIPLEX\u00ae MAP Human Cytokine\/Chemokine\/Growth Factor Panel A. As expected the 183 COVID-19 positive patients had high levels of IgG, IgA and IgM anti-SARS-CoV-2 antibodies against each of the viral proteins. Sensitivity of anti-S1 IgG increased from 60% to 93% one week after symptom onset. S1-IgG and S1-IgA had specificities of 98% compared to the 41 COVID-19 negative patients. The 68 ventilated COVID-19 positive patients had higher antibody levels than the 115 COVID-19 positive patients who were not ventilated. IgG antibody levels against S1 protein had the strongest positive correlation to days from symptom onset. There were no statistically significant differences in IgG, IgA and IgM antibodies against S1 based on age. We found that patients with the highest levels of anti-SARS-CoV-2 antibodies had the lowest viral load in the nasopharynx. Finally there was a correlation of high plasma IL-10 with low anti-SARS-CoV-2 antibodies. Anti-SARS-CoV-2 antibody levels, as measured by a novel antigen panel, increased within days after symptom onset, achieving &gt; 90% sensitivity and specificity within one week, and were highest in patients who required mechanical ventilation. Antibody levels were inversely associated with viral load but did not differ as a function of age. The correlation of high IL-10 with low antibody response suggests a potentially suppressive role of this cytokine in the humoral immune response in COVID-19.\n                <\/jats:p>","DOI":"10.1101\/2020.12.05.20244541","type":"posted-content","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T01:40:51Z","timestamp":1607391651000},"source":"Crossref","is-referenced-by-count":8,"title":["IgG Antibodies against SARS-CoV-2 Correlate with Days from Symptom Onset, Viral Load and IL-10"],"prefix":"10.64898","author":[{"given":"Mary K.","family":"Young","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Kornmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca M.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick R.","family":"Natale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Sasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Solga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy J.","family":"Mathers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda D.","family":"Poulter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"William A.","family":"Petri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2020120908151589000_2020.12.05.20244541v1.1","unstructured":"WHO Weekly Operational Update on COVID-19, 1 December 2020- https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update1-december-2020"},{"key":"2020120908151589000_2020.12.05.20244541v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2521-4"},{"key":"2020120908151589000_2020.12.05.20244541v1.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.5394"},{"key":"2020120908151589000_2020.12.05.20244541v1.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775"},{"key":"2020120908151589000_2020.12.05.20244541v1.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"2020120908151589000_2020.12.05.20244541v1.6","doi-asserted-by":"crossref","unstructured":"Ahmed SF , Quadeer AA , McKay MR . Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses 12 (2020) https:\/\/doi.org\/10.3390\/v12030254","DOI":"10.3390\/v12030254"},{"key":"2020120908151589000_2020.12.05.20244541v1.7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","year":"2020","journal-title":"Nature"},{"key":"2020120908151589000_2020.12.05.20244541v1.8","first-page":"2033","volume":"191","year":"2020","journal-title":"Antigenic Cross-Reactivity between Severe Acute Respiratory Syndrome\u2014Associated Coronavirus and Human Coronaviruses 229E and OC43, The Journal of Infectious Diseases"},{"key":"2020120908151589000_2020.12.05.20244541v1.9","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2\u2212Specific Antibody Responses in Coronavirus Disease Patients","volume":"26","year":"2020","journal-title":"Emerging Infectious Disease"},{"key":"2020120908151589000_2020.12.05.20244541v1.10","first-page":"1","article-title":"Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity","volume":"183","year":"2020","journal-title":"Cell"},{"key":"2020120908151589000_2020.12.05.20244541v1.11","doi-asserted-by":"crossref","unstructured":"Crawford KHD , Dingens AS , Eguia R , Wolf CR , Wilcox N , Logue JK , Shuey K , Casto A , Fiala B , Wrenn S , Pettie D , King NP , Greninger AL , Chu HY , Bloom JD . Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. Journal of Infectious Disease. https:\/\/doi.org\/10.1093\/infdis\/jiaa618","DOI":"10.1093\/infdis\/jiaa618"},{"key":"2020120908151589000_2020.12.05.20244541v1.12","doi-asserted-by":"crossref","first-page":"102911","DOI":"10.1016\/j.ebiom.2020.102911","article-title":"Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity","volume":"58","year":"2020","journal-title":"EBioMedicine"},{"key":"2020120908151589000_2020.12.05.20244541v1.13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","year":"2020","journal-title":"Nat Med"},{"key":"2020120908151589000_2020.12.05.20244541v1.14","first-page":"1","article-title":"Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19","volume":"7","year":"2020","journal-title":"Front. Mol. Biosci"},{"key":"2020120908151589000_2020.12.05.20244541v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2521-4"},{"key":"2020120908151589000_2020.12.05.20244541v1.16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","year":"2020","journal-title":"Nat Med"},{"key":"2020120908151589000_2020.12.05.20244541v1.17","unstructured":"Ng KW , Faulkner N , Cornish GH , Rosa A , Harvey R , Hussain S , Ulferts R , Earl C , Wrobel AG , Benton DJ , Roustan C , Bolland W , Thompson R , Agua-Doce A , Hobson P , Heaney J , Rickman H , Paraskevopoulou S , Houlihan CF , Thompson K , Sanchez E , Shin GY , Spyer MJ , Joshi D , O\u2019Reilly N , Walker PA , Kjaer S , Riddell A , Moore C , Jebson BR , Wilkinson M , Marshall LR , Rosser EC , Radziszewska A , Peckham H , Ciurtin C , Wedderburn LR , Beale R , Swanton C , Gandhi S , Stockinger B , McCauley J , Gamblin SJ , McCoy LE , Cherepanov P , Nastouli E , Kassiotis G. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science (2020). https:\/\/10.1126\/science.abe1107"},{"key":"2020120908151589000_2020.12.05.20244541v1.18","doi-asserted-by":"crossref","unstructured":"Magleby R , Westblade LF , Trzebucki A , Simon MS , Rajan M , Park J , Goyal P , Safford MM , Satlin Mj . Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019. Clinical Infectious Diseases ciaa851, (2020). https:\/\/doi.org\/10.1093\/cid\/ciaa851","DOI":"10.1093\/cid\/ciaa851"},{"issue":"5","key":"2020120908151589000_2020.12.05.20244541v1.19","first-page":"2019","volume":"103","year":"2020","journal-title":"Is Higher Viral Load in SARS-CoV-2 Associated with Death? The American Society of Tropical Medicine and Hygiene"},{"issue":"10","key":"2020120908151589000_2020.12.05.20244541v1.20","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1172\/JCI138759","article-title":"Kinetics of viral load and antibody response in relation to COVID-19 severity","volume":"130","year":"2020","journal-title":"J Clin Invest"},{"key":"2020120908151589000_2020.12.05.20244541v1.21","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343822"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2020.12.05.20244541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:00:50Z","timestamp":1768485650000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2020.12.05.20244541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":21,"URL":"https:\/\/doi.org\/10.1101\/2020.12.05.20244541","relation":{},"subject":[],"published":{"date-parts":[[2020,12,7]]},"subtype":"preprint"}}